Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 17, Issue 4, Pages 547-553Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.4.547
Keywords
antimicrobial therapy; Clostridium difficile; OPT-80
Categories
Ask authors/readers for more resources
Background: Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and more severe clinical cases initiated the search for new treatment options. Objective: OPT-80, also known as tiacumicin B, lipiarmycin or PAR-101, is a macrocyclic antimicrobial with little or no systemic absorption after oral administration and narrow activity spectrum against Gram-positive aerobic and anaerobic bacteria. Methods: Data on OPT-80 available from published studies, presentations at conferences and the manufacturer were collected and reviewed. Results/conclusion: The in vitro studies of OPT-80 and clinical C difficile strains showed high activity at low concentrations. Safety and efficacy of the drug were found to be favourable. More Phase II and III clinical trials are to be completed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available